Latest news and press releases about Pliant Therapeutics, Inc. (PLRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials.
Price
| Price | $1.07 |
| Market Cap | $66M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | -0.86 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -53.22% |
| Return on Invested Capital | -55.49% |
| Return on Assets | -48.60% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ARTV · CLNN · COYA · GUTS · MGNX · OVID
Explore sector: Healthcare · Biotechnology
More sections of PLRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks